Patient Square Capital, a healthcare investment firm, has formed a new portfolio company, Enavate Sciences, to invest in therapeutic and enabling technology companies. Enavate has received an initial capital commitment of $300 million from Patient Square and anticipates significant additional funding to be raised over time.
Enavate Sciences is a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient needs. The firm will provide capital and support to companies to advance the development of novel therapies.
Patient Square Capital is a healthcare investment firm that partners with management teams whose products, services and technologies improve health. Patient Square targets firms in sectors like pharmaceutical value chain, biopharmaceuticals and consumer health.
“Patient Square Capital’s approach to investing in therapeutics focuses primarily on backing talented teams in interesting areas of medicine and progressing multiple clinical programs toward regulatory approval. There are many promising companies with innovative science, however, that do not fit this model,” said Jim Momtazee, managing partner of Patient Square and chairman of the board of directors of Enavate Sciences. “This new platform will support a series of these companies that collectively have similar transformative potential by providing the funds and strategic capabilities necessary to advance therapeutic pipelines, which is particularly important given the scarcity of funding in today’s environment.”